Browsing by Author "Terry Fox Laboratory"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease
    (2005-01-01) W. Eisterer; X. Jiang; O. Christ; H. Glimm; K. H. Lee; E. Pang; K. Lambie; G. Shaw; T. L. Holyoake; A. L. Petzer; C. Auewarakul; M. J. Barnett; C. J. Eaves; A. C. Eaves; Terry Fox Laboratory; Universitatsklinik fur InnereMedizin; Universitat Freiburg im Breisgau; University of Glasgow; Mahidol University; The University of British Columbia
    Xenograft models of chronic phase human chronic myeloid leukemia (CML) have been difficult to develop because of the persistence of normal hematopoietic stem cells in most chronic phase CML patients and the lack of methods to selectively isolate the rarer CML stem cells. To circumvent this problem, we first identified nine patients' samples in which the long-term culture-initiating cells were predominantly leukemic and then transplanted cells from these samples into sublethally irradiated NOD/SCID and NOD/SCID-β2microglobulin-/-mice. This resulted in the consistent and durable (>5 months) repopulation of both host genotypes with similar numbers of BCR-ABL+/Ph+cells. The regenerated leukemic cells included an initial, transient population derived from CD34+CD38+cells as well as more sustained populations derived from CD34+CD38-progenitors, indicative of a hierarchy of transplantable leukemic cells. Analysis of the phenotypes produced revealed a reduced output of B-lineage cells, enhanced myelopoiesis with excessive production of erythroid and megakaropoietic cells and the generation of primitive (CD34+) leukemic cells displaying an autocrine IL-3 and G-CSF phenotype, all characteristics of primary CML cells. These findings demonstrate the validity of this xenograft model of chronic phase human CML, which should enable future investigation of disease pathogenesis and new approaches to therapy. © 2005 Nature Publishing Group. All rights reserved.
  • No Thumbnail Available
    PublicationMetadata only
    Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
    (2019-10-01) Andrea Cossarizza; Hyun Dong Chang; Andreas Radbruch; Andreas Acs; Dieter Adam; Sabine Adam-Klages; William W. Agace; Nima Aghaeepour; Mübeccel Akdis; Matthieu Allez; Larissa Nogueira Almeida; Giorgia Alvisi; Graham Anderson; Immanuel Andrä; Francesco Annunziato; Achille Anselmo; Petra Bacher; Cosima T. Baldari; Sudipto Bari; Vincenzo Barnaba; Joana Barros-Martins; Luca Battistini; Wolfgang Bauer; Sabine Baumgart; Nicole Baumgarth; Dirk Baumjohann; Bianka Baying; Mary Bebawy; Burkhard Becher; Wolfgang Beisker; Vladimir Benes; Rudi Beyaert; Alfonso Blanco; Dominic A. Boardman; Christian Bogdan; Jessica G. Borger; Giovanna Borsellino; Philip E. Boulais; Jolene A. Bradford; Dirk Brenner; Ryan R. Brinkman; Anna E.S. Brooks; Dirk H. Busch; Martin Büscher; Timothy P. Bushnell; Federica Calzetti; Garth Cameron; Ilenia Cammarata; Xuetao Cao; Susanna L. Cardell; Stefano Casola; Marco A. Cassatella; Andrea Cavani; Antonio Celada; Lucienne Chatenoud; Pratip K. Chattopadhyay; Sue Chow; Eleni Christakou; Luka Čičin-Šain; Mario Clerici; Federico S. Colombo; Laura Cook; Anne Cooke; Andrea M. Cooper; Alexandra J. Corbett; Antonio Cosma; Lorenzo Cosmi; Pierre G. Coulie; Ana Cumano; Ljiljana Cvetkovic; Van Duc Dang; Chantip Dang-Heine; Martin S. Davey; Derek Davies; Sara De Biasi; Genny Del Zotto; Gelo Victoriano Dela Cruz; Michael Delacher; Silvia Della Bella; Paolo Dellabona; Günnur Deniz; Mark Dessing; James P. Di Santo; Andreas Diefenbach; Francesco Dieli; Andreas Dolf; Thomas Dörner; Regine J. Dress; Diana Dudziak; Michael Dustin; Charles Antoine Dutertre; Friederike Ebner; Sidonia B.G. Eckle; Matthias Edinger; Pascale Eede; Götz R.A. Ehrhardt; Marcus Eich; Pablo Engel; Britta Engelhardt; Anna Erdei; Institute for Advanced Study of Technical University of Munich; Leibniz-Gemeinschaft; University of Auckland, School of Biological Sciences; A-Star, Singapore Immunology Network; The Francis Crick Institute; Humanitas University; Institut Pasteur - Fondazione Cenci Bolognetti; Istituto Italiano di Tecnologia; Duke-NUS Medical School Singapore; Fondazione IFOM Istituto Firc di Oncologia Molecolare; Fondazione Don Carlo Gnocchi; IRCCS San Raffaele Scientific Institute; Sony Europe Limited, Germany; Miltenyi Biotec; University of Luxembourg; Luxembourg Institute of Health; de Duve Institute; Theodor Kocher Institute of University of Bern; Universiteit Gent; University of Leicester; Thermo Fisher Scientific Inc.; Università degli Studi di Roma La Sapienza; Università degli Studi di Verona; NYU Langone Medical Center; National Cancer Centre, Singapore; University of Cambridge; Københavns Universitet; Universität Regensburg; Freie Universität Berlin; Università degli Studi di Milano; Universitätsklinik Erlangen und Medizinische Fakultät; Lunds Universitet; Universite Paris Descartes; Ludwig-Maximilians-Universität München; Istanbul Üniversitesi; Princess Margaret Cancer Centre; University of Melbourne; Charité – Universitätsmedizin Berlin; Eötvös Loránd University; Humanitas Research Hospital; University of Rochester Medical Center; Université Paris-Sud; Medizinische Hochschule Hannover (MHH); Helmholtz Center Munich German Research Center for Environmental Health; University of Technology Sydney; Università degli Studi di Firenze; Klinikum der Universität Regensburg und Medizinische Fakultät; Technical University of Munich; University of Birmingham; Monash University; Nankai University; Università degli Studi di Palermo; University of Toronto; Göteborgs Universitet; University Hospital Zurich Institute of Experimental Immunology; IRCCS Istituto Giannina Gaslini - Ospedale Pediatrico; Odense Universitetshospital; University of California, Davis; IRCCS Fondazione Santa Lucia; Stanford University; University of Zurich; Universität zu Lübeck; Christian-Albrechts-Universität zu Kiel; University of Milano - Bicocca; Helmholtz Centre for Infection Research (HZI); King's College London; Medizinische Universitat Wien; Danmarks Tekniske Universitet; The University of British Columbia; Istituto Superiore Di Sanita; BC​ Children​'​​s Hospital; Universität Bonn; European Molecular Biology Laboratory Heidelberg; Kennedy Institute of Rheumatology; Universitätsklinikum Schleswig-Holstein Campus Kiel; University College Dublin; Università degli Studi di Modena e Reggio Emilia; Terry Fox Laboratory; Università degli Studi di Siena; Albert Einstein College of Medicine of Yeshiva University; Institut Pasteur, Paris; Universitat de Barcelona; Friedrich-Alexander-Universität Erlangen-Nürnberg; German Center for Infection Research (DZIF); Berlin Institute of Health (BIH); Comprehensive Cancer Center Zurich; Regensburg Center for Interventional Immunology (RCI); Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH); Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research
    © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community. They provide the theory and key practical aspects of flow cytometry enabling immunologists to avoid the common errors that often undermine immunological data. Notably, there are comprehensive sections of all major immune cell types with helpful Tables detailing phenotypes in murine and human cells. The latest flow cytometry techniques and applications are also described, featuring examples of the data that can be generated and, importantly, how the data can be analysed. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid, all written and peer-reviewed by leading experts in the field, making this an essential research companion.
  • No Thumbnail Available
    PublicationMetadata only
    Parallel assessment of globin lentiviral transfer in induced pluripotent stem cells and adult hematopoietic stem cells derived from the same transplanted β-thalassemia patient
    (2013-09-01) Alisa Tubsuwan; Soumeya Abed; Annette Deichmann; Melanie D. Kardel; Cynthia Bartholomä; Alice Cheung; Olivier Negre; Zahra Kadri; Suthat Fucharoen; Christof Von Kalle; Emmanuel Payen; Stany Chrétien; Manfred Schmidt; Connie J. Eaves; Philippe Leboulch; Leïla Maouche-Chrétien; Institut des Maladies Emergentes et des Therapies Innovantes; Universite Paris-Sud XI; Mahidol University; Universite Paris 7- Denis Diderot; German Cancer Research Center; Terry Fox Laboratory; Bluebirdbio France; Brigham and Women's Hospital
    A patient with βE/β0-thalassemia major was converted to transfusion-independence 4.5 years ago by lentiviral gene transfer in hematopoietic stem cells while showing a myeloid-biased cell clone. Induced pluripotent stem cells (iPSCs) are a potential alternative source of hematopoietic stem cells. If fetal to adult globin class, switching does not occur in vivo in iPSC-derived erythroid cells, β-globin gene transfer would be unnecessary. To investigate both vector integration skewing and the potential use of iPSCs for the treatment of thalassemia, we derived iPSCs from the thalassemia gene therapy patient and compared iPSC-derived hematopoietic cells to their natural isogenic somatic counterparts. In NSG immunodeficient mice, embryonic to fetal and a partial fetal to adult globin class switching were observed, indicating that the gene transfer is likely necessary for iPSC-based therapy of the β-hemoglobinopathies. Lentivector integration occurred in regions of low and high genotoxicity. Surprisingly, common integration sites (CIS) were identified across those iPSCs and cells retrieved from isogenic and nonisogenic gene therapy patients with β-thalassemia and adrenoleukodystrophy, respectively. This suggests that CIS observed in the absence of overt tumorigenesis result from nonrandom lentiviral integration rather than oncogenic in vivo selection. These findings bring the use of iPSCs closer to practicality and further clarify our interpretation of genome-wide lentivector integration. Stem Cells 2013;31:1785-1794 © AlphaMed Press.